InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: Amatuer17 post# 3464

Wednesday, 09/19/2018 8:35:38 PM

Wednesday, September 19, 2018 8:35:38 PM

Post# of 3806
Thanks Amateur. I found it in the presentation below.

http://galectintherapeutics.com/wp-content/uploads/2018/07/2018-Galectin-Presentation-Immunooncology-FINAL.pdf

I find it interesting that there were only three patients in Cohort 2 with Yervoy at the 2mg dose and of those three; 2 patients had a Partial Response and the other patient had a Complete Response but the trial was terminated in favor of starting up with Keytruda. I wish it had continued. It would be interesting to see how the two combinations compared head to head (GR-MD-02/Yervoy vs GR-MD-02/Keytruda).

Sounds like there might have been the potential for an interesting bidding war. Maybe there still is...

"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News